Kidney Disease, Chronic Clinical Trial
Official title:
A Multicenter, Randomized, Double-blind, Parallel Group, Placebo Controlled Study to Assess the Efficacy, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Profile of BI 764198 Administered Orally Once Daily for 12 Weeks in Patients With Focal Segmental Glomerulosclerosis
This study is open to adults with a type of kidney disease called primary focal segmental glomerulosclerosis (FSGS). The purpose of this study is to find out whether a medicine called BI 764198 improves the health of the kidneys in people with FSGS. Three different doses of BI 764198 are tested in this study. Participants are put into 4 groups randomly, which means by chance. Three of the groups receive different doses of BI 764198 and one group receives placebo. Participants are in the study for about 4 months. For about 3 months, they take BI 764198 or placebo as capsules once a day. Placebo capsules look like BI 764198 capsules but do not contain any medicine. Participants visit the study site about 10 times. You can participate in this study from your home. In this case a research nurse will visit you for the study visits. Kidney health is assessed based on the analysis of urine samples, which participants collect at home. At the end of the study, the results are compared between the different groups. During the study, the doctors also regularly check the general health of the participants.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03907657 -
Contrast-enhanced Ultrasound as a Screening Tool for Kidney Cancer in Patients With Von-Hippel Lindau
|
Phase 2 | |
| Completed |
NCT02468401 -
Prevention of Contrast Induced Nephropathy in Patients With Advanced Renal Dysfunction Undergoing Coronary Interventions
|
N/A | |
| Completed |
NCT02238067 -
Survey on Anemia Therapy in Patients With Chronic Kidney Disease Not on Dialysis
|
N/A | |
| Completed |
NCT01194154 -
A Study of Methoxy Polyethylene Glycol-epoetin Beta (Mircera) in Participants With Chronic Kidney Disease (PRIMAVERA)
|
Phase 2 | |
| Completed |
NCT02263833 -
An Observational, Prospective, Safety Study of Mircera (Monopegylated Epoetin Beta) in Clinical Practice
|
N/A | |
| Recruiting |
NCT04078750 -
PLATO - Medication Adherence in Transplant Recipients
|
N/A | |
| Recruiting |
NCT05490511 -
Drug-gene-nutraceutical Interactions of Cannabidiol and Tacrolimus
|
Phase 1 | |
| Suspended |
NCT05747053 -
Personalization of Immunosuppressive Treatment for Organ Transplant Recipients
|
Phase 4 | |
| Completed |
NCT03189212 -
Feasibility Study of Telemedicine for Dialysis Patients Awaiting Transplantation
|
N/A | |
| Enrolling by invitation |
NCT05374291 -
The RENAL LIFECYCLE Trial: A RCT to Assess the Effect of Dapagliflozin on Renal and Cardiovascular Outcomes in Patients With Severe CKD
|
Phase 3 | |
| Recruiting |
NCT05033054 -
Effect of SGLT2i on Cardiovascular Biomarkers in Patients With Type 2 Diabetes and CKD Stage 3b-4
|
||
| Completed |
NCT05064267 -
Hemostatic Profiles in Pediatric CKD
|
||
| Not yet recruiting |
NCT03590067 -
Oral Findings in a Group of Egyptian Pediatric Patients at Endstage Renal Disease
|
||
| Recruiting |
NCT04014127 -
Coronary Microvascular Dysfunction in Chronic Kidney Disease
|
||
| Recruiting |
NCT04626323 -
Randomized Study Comparing Metabolic Surgery With Intensive Medical Therapy to Treat Diabetic Kidney Disease
|
Phase 2 | |
| Not yet recruiting |
NCT05774392 -
An Observational Study of Patients With Chronic Kidney Disease
|
||
| Recruiting |
NCT03615235 -
APOL1 Long-term Kidney Transplantation Outcomes Network (APOLLO)
|
||
| Recruiting |
NCT04515797 -
QUICKly Eradicate Hepatitis C in Patients Undergoing REnal Transplant With 4 Weeks of Glecaprevir/Pibrentasvir
|
Phase 4 | |
| Completed |
NCT03850756 -
Early Diagnosis of Kidney Damage Associated With Tobacco Use
|
||
| Recruiting |
NCT05614115 -
Safety, Tolerability, and Feasibility of Empagliflozin Therapy in Dialysis-dependent ESKD
|
Phase 1 |